111 related articles for article (PubMed ID: 7586587)
21. Circulating chromogranin A as a diagnostic tool in clinical chemistry.
O'Connor DT; Takiyyuddin MA; Cervenka JH; Parmer RJ; Barbosa JA; Chang YM; Hsiao RJ
Acta Histochem Suppl; 1990; 38():27-33. PubMed ID: 2080246
[TBL] [Abstract][Full Text] [Related]
22. Secretion of chromogranin A by peptide-producing endocrine neoplasms.
O'Connor DT; Deftos LJ
N Engl J Med; 1986 May; 314(18):1145-51. PubMed ID: 3007986
[TBL] [Abstract][Full Text] [Related]
23. [Chromogranin A, chromogranin B, chromogranin C].
Takekoshi K; Nakai T; Matsui Y
Nihon Rinsho; 1999 Dec; 57 Suppl():234-7. PubMed ID: 10778109
[No Abstract] [Full Text] [Related]
24. Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses.
Giovanella L
Anticancer Res; 2005; 25(3A):1547-50. PubMed ID: 16033058
[TBL] [Abstract][Full Text] [Related]
25. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of laboratory data of 155 patients with pheochromocytoma-paraganglioma syndrome diagnosed during the past 20 years].
Balog B; Tőke J; Róna K; Szücs N; Igaz P; Pusztai P; Sármán B; Gláz E; Kiss R; Patócs A; Rácz K; Tóth M
Orv Hetil; 2015 Apr; 156(16):626-35. PubMed ID: 25864138
[TBL] [Abstract][Full Text] [Related]
27. Chromogranin A in human disease.
O'Connor DT; Mahata SK; Taupenot L; Mahata M; Livsey Taylor CV; Kailasam MT; Ziegler MG; Parmer RJ
Adv Exp Med Biol; 2000; 482():377-88. PubMed ID: 11192598
[No Abstract] [Full Text] [Related]
28. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin A assay in clinical practice.
d'Herbomez M; Do Cao C; Vezzosi D; Borzon-Chasot F; Baudin E;
Ann Endocrinol (Paris); 2010 Sep; 71(4):274-80. PubMed ID: 20538257
[TBL] [Abstract][Full Text] [Related]
30. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma.
Wassberg E; Stridsberg M; Christofferson R
J Endocrinol; 1996 Nov; 151(2):225-30. PubMed ID: 8958782
[TBL] [Abstract][Full Text] [Related]
32. Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma.
Guillemot J; Anouar Y; Montero-Hadjadje M; Grouzmann E; Grumolato L; Roshmaninho-Salgado J; Turquier V; Duparc C; Lefebvre H; Plouin PF; Klein M; Muresan M; Chow BK; Vaudry H; Yon L
Int J Cancer; 2006 Apr; 118(8):2003-12. PubMed ID: 16287097
[TBL] [Abstract][Full Text] [Related]
33. Chromogranin A in uremia: progressive retention of immunoreactive fragments.
Hsiao RJ; Mezger MS; O'Connor DT
Kidney Int; 1990 Mar; 37(3):955-64. PubMed ID: 2313983
[TBL] [Abstract][Full Text] [Related]
34. Characterization of serum and urinary chromogranin A by size exclusion chromatography: impact on calibrator selection and urinary assay.
Tsao KC; Liu GH; Chang PY; Lin CN; Wu TL; Sun CF; Wu JT
J Clin Lab Anal; 2001; 15(4):193-8. PubMed ID: 11436202
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan.
Giovanella L; Squin N; Ghelfo A; Ceriani L
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):344-7. PubMed ID: 17043632
[TBL] [Abstract][Full Text] [Related]
37. Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma.
Mouri T; Sone M; Takahashi K; Itoi K; Totsune K; Hayashi Y; Hasegawa S; Ohneda M; Murakami O; Miura Y
Clin Sci (Lond); 1992 Aug; 83(2):205-11. PubMed ID: 1327637
[TBL] [Abstract][Full Text] [Related]
38. Human pheochromocytoma: different patterns of catecholamines and chromogranins in the intact tumour, urine and serum in clinically unsuspected cases.
Aardal S; Aardal NP; Larsen TH; Angeletti RH; Stridsberg M; Taupenot L; Aunis D; Helle KB
Scand J Clin Lab Invest; 1996 Oct; 56(6):511-23. PubMed ID: 8903113
[TBL] [Abstract][Full Text] [Related]
39. [Chromogranin A in blood--a useful tumor marker].
Syversen U; Heide LS; Waldum HL
Tidsskr Nor Laegeforen; 1997 Oct; 117(26):3810-1. PubMed ID: 9417686
[TBL] [Abstract][Full Text] [Related]
40. Pheochromocytoma: state-of-the-art and future prospects.
Bravo EL; Tagle R
Endocr Rev; 2003 Aug; 24(4):539-53. PubMed ID: 12920154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
